Register Login

Galecto Inc. (GLTO)

(70% Positive) Galecto Inc. (GLTO) Announces Enrollment Update for contained Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:14 a.m.

    📋 Galecto Inc. (GLTO) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:00:32

    Event Type: Clinical Trial Update

    Event Details:

    Galecto Inc. (GLTO) Announces Clinical Trial Update Galecto Inc. (GLTO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: contained, investment
    • Diseases/Conditions: any jurisdiction in which such offer
    • Collaboration: Company
      • anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company’s plan, objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements. Market and Industry Data Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications and other data obtained from third-party sources as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this presentation. Statements as to our market and competitive position data are based on market data currently available to us, as well as management’s internal analyses and assumptions regarding the Company, which involve certain assumptions and estimates. These internal analyses have not been verified by any independent sources and there can be no assurance that the assumptions or estimates are accurate. While we are not aware of any misstatements regarding our industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors. As a result, we cannot guarantee the accuracy or completeness of such information contained in this presentation. Company Logo 2 Galecto acquired potentially best-in-class therapies targeting mutant CALR-driven myeloproliferative neoplasms Acquisition of Damora Therapeutics brings in mutCALR portfolio to address full mutCALR MPN disease spectrum Lead program is a potentially best-in-class, subcutaneous anti-mutCALR mAb Clinical proof-of concept for MOA demonstrated potential to establish new SOC in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) Designed to target both major forms of mutCALR MutCALR-targeted antibodies developed by the Paragon Therapeutics team with deep expertise in rapidly advancing best-in-class biologics Our mission is to transform treatment for patients with myeloproliferative neoplasms (MPNs) Program MoA Stage Discovery IND-enabling Clinical DMR-001 Anti-mutCALR mAb (Fc-null, half-life extended) Two POC readouts, expected mid-2027
      • Targeting lower dose to enable convenient SC autoinjector format Novel IP for composition of matter into 2040
      • targeting mutant CALR-driven myeloproliferative neoplasms Acquisition of Damora Therapeutics brings in mutCALR portfolio to address full mutCALR MPN disease spectrum Lead program is a potentially best-in-class, subcutaneous anti-mutCALR mAb Clinical proof-of concept for MOA demonstrated potential to establish new SOC in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) Designed to target both major forms of mutCALR MutCALR-targeted antibodies developed by the Paragon Therapeutics team with deep expertise in rapidly advancing best-in-class biologics Our mission is to transform treatment for patients with myeloproliferative neoplasms (MPNs) Program MoA Stage Discovery IND-enabling Clinical DMR-001 Anti-mutCALR mAb (Fc-null, half-life extended) Two POC readouts, expected mid-2027

    🔬 Clinical Development Pipeline (Galecto Inc.):

    Product Type Development Stage Therapeutic Area Source
    Medicult IVM DEVICE Phase PHASE3 In Vitro Maturation of Oocytes ClinicalTrials.gov
    Fertilo BIOLOGICAL Phase PHASE3 In Vitro Maturation of Oocytes ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Galecto Inc.
    • Ticker Symbol: GLTO

Search

News categories